Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 3 of 3 for “"Secukinumab"”.
-
The development of a liposomal form Secukinumab – an IL 17 pathway inhibitor in the treatment of psoriasis
… shown great efficacy with fewer side effects, is Secukinumab. Secukinumab is an anti-IL17 antibody that works by stopping the action of IL17, a cytokine that is known to have a major role in the pathogenesis of psoriasis. This work is based on the development of a new way to commence drug therapy …
-
The development of a liposomal form Secukinumab – an IL 17 pathway inhibitor in the treatment of psoriasis
… shown great efficacy with fewer side effects, is Secukinumab. Secukinumab is an anti-IL17 antibody that works by stopping the action of IL17, a cytokine that is known to have a major role in the pathogenesis of psoriasis. This work is based on the development of a new way to commence drug therapy …
-
HIDRADENITIS SUPPURATIVA WITH 20 OR MORE DRAINING TUNNELS: A NATION-WIDE RETROSPECTIVE STUDY.
… 12 received anti-IL17 agents, including secukinumab (9) and bimekizumab (3), and 9 were also offered off-label treatment options, including guselkumab (4), infliximab (3), risankizumab (1) and ustekinumab (1). At univariate regression analysis, gluteal involvement was a negative predictor …